AI assistant
Sending…
RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2026
Mar 3, 2026
30849_dirs_2026-03-02_74190b73-1f55-4fa8-bd6d-abd2eab9a4c3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2026-03-02
Reporting Person: Smith Hunter C (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2026-03-02 | Common Stock | M | 6099 | $6.8 | Acquired | 116611 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2026-03-02 | Stock Options (Right to Buy) | $6.8 | M | 6099 | Disposed | 2032-02-08 | Common Stock (6099) | Direct |
Footnotes
F1: The options are fully vested.
More from RHYTHM PHARMACEUTICALS, INC.
Proxy Solicitation & Information Statement
2026
May 29
Regulatory Filings
2026
May 5
Regulatory Filings
2026
May 5
Proxy Solicitation & Information Statement
2026
Apr 29
Board/Management Information
2026
Apr 3
Major Shareholding Notification
2026
Mar 27
Regulatory Filings
2026
Mar 20
Director's Dealing
2026
Mar 4
Director's Dealing
2026
Mar 4
Regulatory Filings
2026
Mar 2